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Abstract
Metabolic conversion of inorganic arsenic into methylated products is a multistep process that yields
mono-, di-, and trimethylated arsenicals. In recent years, it has become apparent that formation of
methylated metabolites of inorganic arsenic is not necessarily a detoxification process. Intermediates
and products formed in this pathway may be more reactive and toxic than inorganic arsenic. Like all
metabolic pathways, understanding the pathway for arsenic methylation involves identification of
each individual step in the process and the characterization of the molecules which participate in
each step. Among several arsenic methyltransferases that have been identified, arsenic (+3 oxidation
state) methyltransferase is the one best characterized at the genetic and functional levels. This review
focuses on phylogenetic relationships in the deuterostomal lineage for this enzyme and on the relation
between genotype for arsenic (+3 oxidation state) methyltransferase and phenotype for conversion
of inorganic arsenic to methylated metabolites. Two conceptual models for function of arsenic (+3
oxidation state) methyltransferase which posit different roles for cellular reductants in the conversion
of inorganic arsenic to methylated metabolites are compared. Although each model accurately
represents some aspects of enzyme’s role in the pathway for arsenic methylation, neither model is a
fully satisfactory representation of all the steps in this metabolic pathway. Additional information
on the structure and function of the enzyme will be needed to develop a more comprehensive model
for this pathway.
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Elucidation of the pathway for conversion of inorganic arsenic (iAs) to methylated metabolites
began in the 19th century with studies in microorganisms and led to identification of
trimethylarsine (TMA) as a volatile metabolite (1). Implicit in identification of this highly
methylated arsenical as a metabolite was the possibility that other methylated arsenicals might
be formed as intermediates in this pathway. Furthermore, widespread recognition that humans
who ingested iAs often exhibited a strong garlic-like odor on expired breath led to a common
understanding that humans must also form methylated arsenicals. Following Braman and
Foreback (2) who reported the presence of iAs, methyl arsenic (MA), and dimethyl arsenic
(DMA) in human urine, Crecelius (3) provided the first definitive report of the presence of
these arsenicals in the urine of a volunteer who ingested wine or water containing inorganic
arsenite (iAsIII) or inorganic arsenate (iAsV). This result was consistent with the hypothesis
that there is a metabolic pathway leading from iAs to these methylated products. Studies in
humans and other species have provided a general understanding of the characteristics of the
distribution, metabolism, retention, and excretion of arsenicals (4,5). In particular, these studies
show that many animal species convert iAs into MAs and DMAs, which are excreted in urine.
Determining the basis for this conversion of iAs into methylated species depended on
development of strategies to isolate, purify, and characterize the molecules that are involved
in each step of the pathway that leads from iAs to its methylated metabolites and development
of sufficiently sensitive and specific analytical methods to identify intermediates and products
formed in the methylation pathway.
Although the details of the pathway for arsenic (As) methylation will be discussed in the course
of this review, it is sufficient to say that it has commonly been assumed that the pathway leading
from iAs to the methylated metabolites involves several distinct steps. In this process, oxidative
methylation of arsenicals alternates with reductive processes, yielding a number of
intermediates and products. Some steps in this pathway have been reported to be strictly
chemical reactions; others are enzymatically catalyzed. Many details of this pathway and the
nature of each constituent steps remain uncertain (for a review of some of these controversies,
see Ref. 6). However, work to date has identified one methyltransferase that is clearly a
participant in this pathway. Arsenic (+3 oxidation state) methyltransferase (AS3MT)1
catalyzes conversion of iAs to methylated products. This review examines the occurrence of
AS3MT homologs in genomes of species ranging from sea urchins to humans and the
association of occurrence of AS3MT and the As methylation phenotype; that is, the capacity
to convert iAs to methylated products that can be detected in tissues and excreta. Finally,
consideration of two conceptual models for As methylation by AS3MT suggests that elements
of either model may be required to describe fully the role of cellular reductants in the catalytic
function of this enzyme.
Phylogenetic Relations for AS3MT
Sequence Homologies in AS3MT
The AS3MT protein was the first As methyltransferase to be sufficiently purified to permit
cloning of the corresponding gene (7,8). Sequence information on rat AS3MT has provided a
starting point to seek a broader perspective on its structure and function as an As
methyltransferase, using genomic data to investigate the occurrence of homologous genes
across a wide range of species. Inspection of predicted products for these AS3MT homologs
1This protein and its gene were initially termed cyt19 by us and other investigators, following its original identification in GenBank with
a methyltransferase of unknown function (NCB accession NP065602 and NP 05133). Subsequently, we have followed the
recommendations of the Human Genome Nomenclature Committee (http://www.gene.ucl.ac.uk/cgi-bin/nomenclature/searchgenes.pl)
for the systematic naming of genes and proteins and refer to protein or gene as arsenic (+3 oxidation state) methyltransferase (AS3MT).
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identified proteins encoded in genomes of purple sea urchin (Strongylocentrotus purpuratus),
sea squirt (Ciona intestinalis), rainbow trout (Oncorhynchus mykiss), chicken (Gallus
gallus), rat (Rattus norvegicus), mouse (Mus musculus), cow (Bos taurus), chimpanzee (Pan
troglodytes), and human (Homo sapiens). Alignments of predicted protein products of these
AS3MT homologs identified several common features (Table 1). For all species except Pan,
AS3MT ranged from 348 residues (Ciona) to 382 residues (Gallus). All AS3MT sequences
contained multiple cysteine residues ranging from five in the truncated Pan sequence to 15 in
the Gallus sequence. Among all predicted AS3MT sequences, there were five fully conserved
cysteines. Based on the 375 residue sequence of Homo AS3MT, these are cysteines in positions
32, 61, 85, 156, and 206. Predicted AS3MT proteins contained three sequence motifs common
to many S-adenosylmethionine (AdoMet)–dependent methyltransferases that catalyze
methylation of proteins and small molecules (9). Interactions between AdoMet and these
conserved amino acid motifs are critical for methyl group transfer to substrate (10). Motif I,
with a consensus sequence of (V/I/L)(L/V)(D/I)LG(G/C)G(T/P)G with an invariant G in
position 5 occurred as the sequence (I/V/ L)LDLGSGSG in AS3MT. This sequence in AS3MT
conformed to the rule of hh (D/E)hGXGXG, where h was a hydrophobic amino acid, and X
was any amino acid. Like other AdoMet-dependent methyltransferases, the predicted products
of AS3MT in these species contained a conserved aspartate at 20 residues C-terminal to Motif
I. This aspartate occurred in the common postmotif I in other methyltransferases (hhXh(D/E)).
Motif II was found 65 residues C-terminal to Motif I in all AS3MT sequences. The Motif II
consensus sequence ((P/G)(Q/T)(F/Y/A)DA(I/V/Y)(F/I)(C/ V/L) with an invariant aspartate
at position 4 occurred as the sequence (E/N/T)(S/A)(Y/H/M/F)DI(V/I)(I/V)S in AS3MT. Motif
III occurred 20 residues C-terminal to Motif II in the AS3MT sequences as VL(K/N)(H/Y/E/
P/D)GGE(L/M/ F)YF. The consensus sequence for Motif III (LL(R/ K)PGG(R/I/L)(L/I)(L/F/
I/V)(I/L)) has at least one of the two glycine residues conserved in most methyltransferases.
Origins and Functions of AS3MT
The arsM gene has been identified as bacterial and archaeal homologs of AS3MT (11). ArsM
protein of Rhodopseudomonas palustris catalyzes the formation of methylated arsenicals from
iAsIII. AS3MT homologs occur widely in genomes of many deuterostomes, ranging from
relatively simple species (S. purpuratus, C. intestinalis) to H. sapiens. Because AS3MT
homologs have not been identified in the genomes of two protostomes, Drosophila
melanogaster or Caenorhabditis elegans, it may have arisen in the deuterostomal lineage after
the division of bilaterian animals into deuterostomal and protostomal superphyla about 656 to
575 million years before present (12). Notably, a recent study found no methylation of iAs in
D. melanogaster larvae or adults (13), consistent with the absence of AS3MT from its genome.
Identification of AS3MT homologs in the genomes of Strongylocentrotus and Ciona suggests
that this gene arose before the division of chordates and nonchordates. Although about 60%
of identified Ciona genes have homologs in protostomes, about 16% of Ciona genes lack
homologs among protostomes (14). Alternatively, the absence of AS3MT in Drosophila and
Caenorhabditis genomes could be an example of lineage-specific loss of a gene present in some
ancestral genome (15).
Evidence of iAs methylation in protostomes, including the polychaetes, Nereis diversicolor
and N. viriens, may provide some insight into phylogenetic relations for AS3MT. For these
species, tetramethylarsinonium ion and arsenobetaine are the predominant arsenicals in
Nereis tissues after exposure to arsenate; however, a small amount of the tissue arsenic is
present as MAs (16). In another polychaete, Arenicola marina, most tissue arsenic is present
as inorganic species with small percentages (~5%) present as arsenobetaine and DMAs (17).
These patterns, especially the predominance of the tetramethylated form, are not consistent
with the pattern seen in species in which AS3MT methylates arsenicals. For instance,
tetramethylarsinonium ion is a minor constituent (<1%) in urine of rats treated with arsenite
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(18). Differences in metabolic profiles in polychaetes and in species in which AS3MT is
expressed suggest that the pathway for arsenic methylation in polychaetes may involve other
enzymes, not AS3MT.
At least three explanations can be offered for the persistence of AS3MT homologs in the
genomes of organisms representing the deuterostomal lineage. First, capacity to methylate
inorganic As could be a mechanism for the detoxification of this metalloid. However, because
AS3MT-catalyzed methylation of iAs yields products that are more reactive and toxic than the
parent compound (19), the persistence of AS3MT would be dependent on the balance of the
advantageous and deleterious effects of methylation of arsenicals. Second, methylation of iAs
by AS3MT could yield a metabolite that is essential for normal cellular function. Studies in
experimental species (rat, hamster, minipig, goat, and chicken) suggest arsenic to be an
essential nutrient (20). For example, consumption of diets with low concentrations (ng per g
range) of iAs have been associated with lower growth rates and decreased reproductive success
in these species. Additional studies have demonstrated interactions between dietary
deficiencies of iAs, methionine, and pyridoxine (21). Although the molecular bases for these
actions of arsenic have not been determined, the salutary effects of iAs in diet might be due to
an uncharacterized function of a methylated metabolite of iAs. If this conjecture is correct,
then AS3MT could be vital for the production of this methylated species. Third, persistence of
AS3MT may reflect a function of the protein that is not related to its capacity to catalyze
methylation of arsenicals. For example, AS3MT could catalyze the methylation of other
metalloids, such as selenium (Se) or tellurium (Te), or of another class of substrates. In this
situation, catalysis of the methylation of arsenicals by AS3MT would be simply fortuitous.
Genotype-Phenotype Correlations for Arsenic Methylation and AS3MT
The As methylation phenotype is defined as the capacity to convert arsenicals to methylated
forms that are present in tissues and/or excreted in urine. An absolute dependence of As
methylation phenotype on AS3MT genotype can be demonstrated in cultured cells. The
heterologous expression of rat AS3MT in a simian virus 40 (SV40)-transformed human
urothelial (UROtsa) cell line confers the capacity to methylate iAs on cells that otherwise do
not express AS3MT and that have a null phenotype for iAs methylation (22). Conversely,
silencing of AS3MT expression by RNA interference reduces the capacity for methylation of
iAs in human hepatoma (HepG2) cells (23). Among animal species examined in this study,
homologous proteins with essential characteristics of AS3MT can be deduced from genomic
data. For all species, except Strongylocentrotus and Ciona (for which there are no data on As
phenotype), there is an association between the AS3MT genotype and the As methylation
phenotype (Table 2). These data on patterns of metabolites of iAs found in tissue and excreta
of species ranging from Oncorhynchus to Homo indicate that methylated metabolites are
formed in all of these species, except Pan. As previously suggested, the predicted 205 amino
acid product of AS3MT in Pan may be catalytically inactive (25), and the expression of the
truncated protein could account for null phenotype for As methylation reported in this species
(26). As a caveat, data in Table 2 on the pattern of methylated arsenicals should be regarded
as provisional and incomplete. Earlier studies in Bos and Oncorhynchus used analytical
techniques that may not resolve fully mono- and dimethylated arsenicals. The absence of
trimethylarsine oxide (TMAO) as a metabolite in most species may also reflect limitations of
analytical methods used in earlier studies. Similarly, an early study (27) of iAs metabolism in
the green sea urchin Strongylocentrotus droebachiensis, which might provide evidence of iAs
methylation in echinoderms, should be interpreted with caution. A systematic survey with
adequate analytical methods would be needed to ascertain the possible significance of
interspecies difference in the patterns of metabolites and the relation between this phenotypic
variation and genotypic differences among species.
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Conceptual Models for Arsenic Methylation by AS3MT
Two conceptual models are currently available to describe the steps involved in the
enzymatically catalyzed methylation of arsenicals by AS3MT. The first model grows out of
the work of Frederick Challenger and his colleagues in the first half of the twentieth century.
These studies were summarized in two comprehensive reviews (27,28) that outlined a scheme
in which the oxidative methylation of arsenicals containing AsIII alternated with the reduction
of arsenicals containing AsV to trivalency. William Cullen et al. (29) summarized this general
scheme for biological methylation of arsenicals:
(1)
Here, metabolites are produced in sequence as monomethylated, dimethylated, and
trimethylated arsenical species. Neither the methyl donor (Me+) nor the source of reducing
equivalents is identified. The stated order of reactions is oxidative methylation followed by
reduction; therefore, methylated arsenicals containing AsIII should be found as intermediates
in reactions. A more detailed sequence explicitly shows this reaction order. The substrate for
the oxidative methylation reaction contains AsIII, and reduction of the oxidized arsenical
precedes oxidative methylation.
(2)
Although more detailed, this model specifies neither the source of methyl groups nor of
reducing equivalents used in these reactions.
The second conceptual model takes a different approach to the reactions involved in the
methylation of arsenicals (30). Here, thiol-containing complexes of arsenicals containing
AsIII are substrates for sequential reactions that transfer methyl groups to the arsenical. This
general scheme can be summarized as follows:
(3)
In this model, methylation occurs by a nonoxidative mechanism and thiol-arsenical complexes
are obligatory substrates for methylation reactions.
The validity and utility of the two conceptual models can be evaluated in reactions in which
AS3MT is the enzymatic catalyst. Studies with recombinant rat AS3MT (31) and human
recombinant AS3MT (30) have examined in some detail the steps involved in the methylation
of arsenicals catalyzed by this enzyme. Figure 1 provides more detailed descriptions of the
conceptual models under consideration. Model A follows the work of Cullen et al. (29) and
experimental results obtained with recombinant rat AS3MT, and Model B is based on the work
of Hayakawa et al. (30). In both models, AdoMet is the methyl group donor. In Model A, three
linked reactions (1, 2, and 3) involve oxidative methylation followed by reduction. The source
of reducing equivalents needed to reduce AsV to AsIII is not specified. The reactions are linked
by common metabolites (MAsIII and DMAsIII) that are both products for a first reaction and
substrates for a second reaction. In Model B, complexation of inorganic AsIII by the thiol-
containing tripeptide glutathione (GSH) produces a substrate that acquires, in turn, two methyl
groups. Here, reactions 1 and 2 overlap as the product of the first methylation step is the
substrate for the second methylation reaction. The possibility of a third methylation reaction
is not considered in Model B. The presence of MAsIII and DMAsIII in reactions is attributed
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to decomposition of the GSH-arsenical complexes, and the presence of MAsV and DMAsV is
attributed to the oxidation of the methylated arsenicals containing AsIII.
Catalytic Functions for AS3MT
Activity in the Presence of Various Reductants and the Role of GSH
AS3MT was initially purified from the cytosolic fraction of the liver of adult male Fischer 344
rats, using pH-dependent fractionation, chromatofocusing, and S-adenosylhomocysteine-
affinity chromatography (7). This procedure purified several thousand-fold a ~42 kDa protein
that catalyzed the conversion of iAsIII to MAs and DMAs in reactions that depended on AdoMet
as the methyl-group donor. Notably, the success of this scheme for purification of AS3MT
from liver cytosol depended on the presence of 1 mM dithiothreitol (DTT) and 5 mM GSH in
buffers used in each fractionation and chromatographic step. In the absence of either reductant,
As methylating activity was quickly lost during purification. Hence, in initial studies, assays
of the As methylating activity of AS3MT were conducted with both reductants in reaction
mixtures.
Initial studies investigated the patterns of methylation of arsenicals by recombinant rat AS3MT
in reaction mixtures in which different reductants were present (31). Because studies with
nonphysiological reductants like DTT provided little information about the role of reductants
in catalysis by AS3MT, primary emphasis has been placed on the role of potential physiological
reductants in support of the enzyme’s function. This approach was also strongly influenced by
evidence that AS3MT might function as an AsV reductase. In this assay system, formation of
MAs and DMAs proceeded in the presence of AS3MT, a reductant, AdoMet, and an arsenical
substrate. This suggested that reduction of pentavalent arsenicals formed in the assay mixture
could be catalyzed by AS3MT. Other studies with prokaryotic and eukaryotic AsV reductases
indicated that three physiological reductants (thioredoxin, Trx; glutaredoxin, Grx;
dihydrolipoic acid, DHLA) could provide reducing equivalents needed to produce AsIII (32).
Notably, each of these reductants contains a dithiol pair that is oxidized to a disulfide during
reduction of an oxidized substrate. The regeneration of the dithiol pair in each of these
reductants is accomplished by enzymatically catalyzed transfer of reducing equivalents from
nicotinamide adenine dinucleotide phosphate (NADPH). For Trx and DHLA, Trx reductase
(TR) catalyzes the reduction; for Grx, GSH and GSH reductase (GR) are required.
The capacity of different reductants to support catalysis of As methylation by AS3MT was
determined in the absence or presence of 5 mM GSH (Fig. 2). Notably, in the absence of another
reductant, addition of 5 mM GSH did not support the catalytic activity of AS3MT. Although
addition of GSH had little effect on the rate of As methylation in the presence of 1 mM DTT,
it sharply stimulated the methylation rate in the presence of 1 mM Tris (2-carboxylethyl)
phosphine (TCEP). Compared with these nonphysiological reductants, the highest rates of
methylation were found in assays containing a Trx/TR/NADPH–coupled system. Here,
addition of GSH had little effect on an already high rate of As methylation. The activity of Grx
as a reductant depended on addition of GSH to the reaction mixture, reflecting its role in a Grx/
GSH/GR/NADPH–coupled system. DHLA also functioned as reductant when added in a
DHLA/TR/NADPH–coupled system. Furthermore, the presence of methylated arsenicals
containing either AsV or AsIII in reaction mixtures was consistent with the formation and
conversion of these species as the reaction progressed. Several conclusions can be drawn from
these studies. First, among physiological reductants, addition of Trx to reactions at
concentrations approximating those found in cells (33) yielded the highest catalytic activity
for AS3MT. Second, for both physiological and nonphysiological reductants, addition of GSH
stimulated the overall rate for As methylation. Third, under these assay conditions, addition of
GSH resulted in little, if any, conversion of iAs to methylated metabolites.
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In the course of identifying a trimethylated arsenical as a product of AS3MT-catalyzed
reactions, the role of GSH in catalysis was further investigated (34). Although TMAO was
rarely detected in reaction mixtures that contained 5 mM GSH, it accounted for nearly half of
the methylated products present in reaction mixtures that contained AS3MT, AdoMet, iAsIII,
and TCEP but no GSH (Fig. 3). Notably, in the absence of GSH, a physiological reductant
(Trx/TR/NADPH) also supported the formation of TMAO in AS3MT-catalyzed reactions.
Increasing the concentration of GSH in reaction mixtures affected the pattern and extent of As
methylation, suppressing formation of TMAO but increasing overall production of methylated
products. This suggested that the third methylation reaction was inhibited by GSH. When
DMAsIII or dimethylthioarsenite-GSH (a 1:1 molar complex of DMAsIII and GSH) was used
as substrate for AS3MT-catalyzed reactions (final concentration of 1 μM), TMAO was formed
(Fig. 4). When 5 mM GSH was added to assay mixtures containing 1 μM DMAsIII, TMAO
was not formed. This suggested that interactions between AS3MT and GSH that modulate the
enzyme’s activity do not involve a specific role for an arsenical-GSH complex but rather reflect
a direct interaction between the enzyme and GSH.
GSH-Dependent Activity
Model B proposes that As-GSH complexes are both the substrates for, and products of,
reactions catalyzed by AS3MT. Thus, although the methylation of arsenicals requires AsIII, it
must be present in a GSH-containing complex. Furthermore, methylation does not oxidize
AsIII but yields a complex containing a methylated arsenical and GSH. This model requires
scission of an AsIII-S bond between the cysteinyl residue of GSH and AsIII. For studies of the
role of GSH in AS3MT-catalyzed methylation, Hayakawa et al. (30) used reaction mixtures
containing 50 μg of recombinant human AS3MT, 0.2 μM iAsIII, and 1 mM AdoMet in 25
mM phosphate buffer, pH 7. GSH concentration ranged from 0 to 5 mM and reactions were
incubated for 3 hrs at 37°C. Under these conditions, methylated products were detected only
in the presence of at least 2 mM GSH. The investigators found a positive relation between the
percentage of concentration of iAsIII present in an iAsIII-GSH complex (at a 1:3 molar ratio of
iAsIII to GSH) and the extent of AS3MT-catalyzed methylation (Fig. 5). A MAsIII-GSH
complex (at a 1:2 molar ratio of MAsIII to GSH) added to reaction mixtures was rapidly
oxidized to MAsV and was not converted to DMAs. However, the presence of 5 mM GSH in
reaction mixtures permitted the MAsIII-GSH complex to be converted to DMAs by AS3MT.
In the absence of GSH, MAsV was not a substrate for methylation by AS3MT. However,
addition of 5 mM GSH to the reaction mixture permitted formation of a small amount of
MAsIII-GSH complex that was converted to DMAs.
Recent work with recombinant human AS3MT has examined the role of reductants, including
the Trx/TR/NADPH–coupled system and GSH.2 Here, reaction mixtures contained 3 to 5 μg
of recombinant human AS3MT, 3 μM iAsIII, and 1 mM AdoMet in 100 mM Tris, 100 mM
phosphate buffer, pH 7.4. Concentrations of Trx, TR, NADPH, and GSH varied in reaction
mixtures and are indicated in figure legends. As shown in Figure 6, AS3MT catalyzed
conversion of iAs to MAs and DMAs in the presence of the complete Trx/TR/NADPH–coupled
system; however, omission of Trx from reaction mixtures abolished activity. In the presence
of 1 mM GSH, conversion of iAs to MAs and DMAs was stimulated. Again, omission of Trx
from reaction mixtures containing GSH sharply reduced activity. A small amount of MAs was
detected in these reaction mixtures, suggesting a minimal effect of GSH on AS3MT’s catalytic
activity. Examination of the concentration dependence of the effect of GSH on the activity of
AS3MT in reaction mixtures containing the Trx/TR/ NADPH–coupled system showed that
GSH stimulated the rate of conversion of iAs to MAs and DMAs (Fig. 7).
2Xing W, Adair BW, Thomas DJ. Unpublished results, 2006.
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Merits and Limitations of the Conceptual Models for Arsenic Methylation by AS3MT
The first conceptual model involving alternating steps of oxidative methylation and reduction
of arsenicals can serve as a framework for understanding the role of cellular reductants in
catalytic activity of AS3MT. However, two general questions must be addressed in evaluating
the function of these cellular reductants. First, how do these reductants act to promote the
catalytic activity of the enzyme? Second, how does the function of these reductants complement
the actions of GSH? The use of cellular reductants by AS3MT is reminiscent of the role of
these reductants in the activity of several well-characterized AsV reductases. These enzymes
use Trx/TR/NADPH– or Grx/GSH/GR/NADPH–coupled systems as the source of reducing
equivalents for conversion of AsV to AsIII (32). Because AS3MT catalyzes each step in a
reaction sequence that leads from iAs to TMAs, it is conceivable that this protein is
multifunctional, catalyzing both oxidative catalysis and reduction of AsV. However, it should
be noted that AS3MT activity is absolutely dependent on the presence of the complete Trx/
TR/NADPH–coupled system; omission of Trx abolishes activity. This suggests that Trx is not
only needed to reduce methylated intermediates containing AsV (e.g., MAsV) but is also
required for AS3MT to catalyze the reaction in which iAsIII is present as the substrate. This
suggests that Trx could be required for the reduction of some cysteine residue in AS3MT that
is critical for its function as a methyltransferase.
The second conceptual model is dependent on interactions between GSH, arsenicals, and
AS3MT. Speculation about the role of GSH in As methylation was first summarized by
Thompson (35), who integrated much of the evidence on the reduction of pentavalent arsenicals
by GSH and the role of GSH complexes in the enzymatically catalyzed methylation of As.
Although GSH can reduce AsV to AsIII in cellular environments and forms stable complexes
with AsIII (36–38), good quantitative estimates are lacking the extent of reduction by this
pathway or the persistence of these complexes in cellular environments. Although DMAsIII
present in a GSH complex could be converted to TMAO, it is not certain if the complex was
the substrate for methylation. It is entirely possible that DMAsIII could be transferred from the
GSH complex to a higher affinity binding site on AS3MT. Hence, the GSH complex would
serve only to maintain arsenic in a reduced state before its interaction with the enzyme. Data
on the effects of GSH on iAs methylation in assay systems using crude cytosol or in tissue
slices (39–41) provide little insight into the molecular processes that underlie the effects of
GSH on enzymatically catalyzed methylation. It is possible that GSH functions to maintain
the correct mix of reduced and of oxidized cysteine residues in AS3MT. The presence of
multiple cysteines in this protein raises the distinct possibility that formation of intramolecular
or intermolecular disulfide bonds affect the structure and function of the enzyme.
Conclusions and Future Directions
Similarities in the sequences of the predicted protein products of AS3MT homologs found in
genomes of a variety of deuterostomes argue that this ubiquitous protein serves a function that
is conserved among these organisms. If the conserved function of these AS3MT homologs is
catalysis of As methylation, then there has been a persistent selective pressure for the capacity
of the protein to catalyze this reaction. Further understanding of the function of AS3MT
depends on physicochemical studies probing its interactions with substrates and with critical
reductants. Site-directed mutagenesis offers the possibility of identifying specific amino acid
residues required for its catalytic activity. Altered expression of AS3MT in cultured cells using
RNA interference could be used to examine effects of altered AS3MT expression on the As
methylation phenotype. AS3MT gene knockouts can be used to examine the As methylation
phenotype and the toxicological consequences of altered capacity to methylate arsenicals.
Examining evidence on the catalytic activity of AS3MT in relation to the two conceptual
models for As methylation supports the conclusion that its activity does not strictly depend on
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the presence of GSH. Methylation occurs in reaction mixtures that contain only the Trx/TR/
NADPH–coupled system as a source of reducing equivalents. Because different laboratories
assay As methylation rates under different experimental conditions (e.g., enzyme
concentration, buffer pH, analytical methods), quantitative comparisons of data obtained in
different laboratories are problematic. However, rates of conversion of iAs to methylated
metabolites using recombinant human AS3MT are much higher in reaction mixtures containing
Trx/TR/ NADPH than in reaction mixtures containing GSH as the sole reductant. Using data
from the work of Hayakawa et al. (fig. 5 in Ref. 30), a methylation rate of 0.1 pmols of
methylated substrate per μg of protein per hr was calculated for reaction mixtures containing
0.2 μM iAsIII as substrate and 5 mM GSH as the reductant. By comparison, a methylation rate
of 0.8 pmols of methylated substrate per μg of protein per hr was calculated for reaction
mixtures containing 0.3 μM iAsIII as substrate and 5 μM Trx, 1 μM TR, and 300 μM NADPH
as the source of reducing equivalents.3 In general, it can be suggested that the presence of GSH
in reaction mixtures stimulates rates of reactions catalyzed by AS3MT that are supported by
other physiological reductants. The nature of the interaction between physiological reductants
and AS3MT that underlie the catalytic functions of the enzyme is unknown. Do the
physiological reductants serve as a source of reducing equivalents needed to reduce AsV to
AsIII, or do the reductants help maintain the critical cysteine residues in the reduced state?
Characterizing these interactions as well as interactions between AS3MT and GSH is an
outstanding research problem that will require considerable ingenuity to solve. Studies of the
catalytic function of common polymorphisms of AS3MT may provide cogent insights into the
relation between enzyme structure and function (42).
A broader research topic grows out of this research on interactions between arsenicals,
reductants, and AS3MT in reaction mixtures in which all elements present in the system are
known and quantified. Cells have redundant systems for reduction, including GSH, Trx, Grx,
and DHLA. The availability of each reductant is tightly regulated by biosynthetic control (e.g.,
GSH synthesis regulated by activity of glutamate-cysteine ligase; Ref 43), and there is evidence
of interactions between reductants that affect their reactivity and concentration (e.g.,
glutathionylation of Trx; Ref. 44). Because AS3MT promiscuously uses each of these
physiological reductants to support catalysis, its activity in cells must be determined at least
in part by concentrations of several reductants. Availability of the reductants could contribute
to the observed dose-dependency of the rate of methylation of iAs in cultured primary human
hepatocytes (45). Similarly, differences in rates of methylation of iAs in cultured cells derived
from different donor species or in intact organisms of different species could reflect interspecies
differences in the concentrations of the reductants needed to support the catalytic activity of
AS3MT. Integrating information on the regulation of AS3MT by reductants poses a
considerable challenge in elucidating the control of As methylation at the cellular and systemic
levels.
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Conceptual models for methylation of inorganic arsenic catalyzed by AS3MT. In Model A,
oxidative methylation of trivalent arsenicals alternates with reduction of pentavalent arsenicals.
In this pathway, arsenite (iAsIII) is converted to methylarsonic acid (MAsV), which is reduced
to methylarsonous acid (MAsIII). This arsenical is converted to dimethylarsinic acid
(DMAsV), which is reduced to dimethylarsinous acid (DMAsIII). This dimethylated species is
converted to trimethylarsine oxide (TMAsV), which is reduced to trimethylarsine (TMAsIII).
Model B involves the sequential addition of methyl groups to trivalent arsenicals that are
complexed to glutathione (GSH). In each model, S-adenosylmethionine (AdoMet) is the methyl
group donor; S-adenosylhomocysteine (AdoHcy) is produced by removal of a methyl group
from AdoMet.
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Effect of glutathione (GSH) on capacity of reductants to support the methylation of inorganic
arsenic by recombinant rat AS3MT. Reaction mixtures (50 μl) containing 5 μg of recombinant
rat AS3MT, 1 mM AdoMet, and 1 μM [73As]-iAsIII in 100 mM Tris/100 mM Na phosphate
buffer, pH 7.4, with or without reductant, were incubated at 37°C for 20 mins. Reactions were
run in the presence or absence of 5 mM GSH. Reductants were 1 mM dithiothreitol (DTT), 1
mM Tris(2-carboxyethyl) phosphine (TCEP), 10 μM Escherichia coli thioredoxin (Trx) with
3 μM rat liver Trx reductase and 300 μM NADPH, 1 μM E. coli glutaredoxin 1 (Grx) with 15
nM yeast GR, 300 μM NADPH, 100 μM dihydrolipoic acid (DHLA) with 3 μM rat liver Trx
reductase, and 300 μM NADPH. Methylation rate calculated as nmols of arsenite methylated
per μg of protein per 20 mins. (Upper) Mean and (lower) standard deviation shown (n = 3).
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Effect of the concentration of glutathione (GSH) on the pattern of metabolites produced by
recombinant rat AS3MT. Reaction mixtures (50 μl) containing 5 μg of recombinant rat
AS3MT, 1 mM AdoMet, 1 mM Tris(2-carboxyethyl) phosphine, and 1 μM [73As]-iAsIII in 100
mM tris/100 mM Na phosphate buffer, pH 7.4, were incubated at 37°C from 20 mins to
overnight (16 hrs) in the presence of 0–10 mM of GSH. Reaction products separated by thin-
layer chromatography as previously described (34). Positions for migration of inorganic arsenic
(iAs), methylarsonic (MAs), dimethylarsinic (DMAs), and trimethylarsine oxide (TMA) are
indicated. Arrow shows direction of chromatography.
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Effect of glutathione (GSH) on rat recombinant AS3MT-catalyzed methylation of
dimethylarsenicals. Reaction mixtures (50 μl) contained 5 μg of rat recombinant AS3MT, 1
mM AdoMet, and 1 mM TCEP. The substrates were 1 μM dimethylarsinous acid, iodide salt
(DMAsIII), 1 μM of an equimolar complex of dimethylarsinous acid with GSH (DMAsIIIGS),
or 1 μM DMAsIII and 5 mM GSH. Reactions were incubated at 37°C for 120 mins and oxidation
states of arsenicals in reaction mixtures were determined by pH selective hydride generation-
atomic absorption spectrophotometry. Percentages of arsenic present as (White) DMAsIII,
(Gray) DMAsV, or (Black) TMAO are shown.
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Glutathione (GSH)-dependent conversion of arsenite to methylated arsenicals by recombinant
human AS3MT. Relationship between the percentage of iAsIII converted to methylated (MAs)
or dimethylated (DMAs) species and the percentage of iAsIII present in an triglutathione
complex (As(GS)3) as GSH concentration increases from 0 to 5 mM. Reaction mixtures (100
μl) containing 50 μg of recombinant rat AS3MT, 1 mM AdoMet, and 0.2 μM iAsIII in 25
mM phosphate buffer, pH 7.0, were incubated at 37°C for 3 hrs. (Redrawn from data in fig. 5
of Ref. 30).
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Effects of glutathione (GSH) and a thioredoxin (Trx)-coupled reduction system on the activity
of recombinant human AS3MT. Reaction mixtures (80 μl) containing 3 μg of recombinant
human AS3MT, 1 mM AdoMet, and 3 μM [73As]-iAsIII in 100 mM Tris/100 mM Na phosphate
buffer, pH 7.4, were incubated at 37°C from 60 mins in the presence or absence of 1 mM GSH.
Complete reaction mixtures contained 3 μM E. coli thioredoxin (Trx) with 1 μM rat liver Trx
reductase and 300 μM NADPH; Trx was omitted from some reaction mixtures (–Trx).
Percentages of arsenic present as (Open) inorganic arsenic, (Black) methylarsonic, and (Gray)
dimethylarsinic species are shown.
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Glutathione (GSH) concentration dependency of the activity of recombinant human AS3MT.
Reaction mixtures (80 μl) containing 4 μg of recombinant human AS3MT, 1 mM AdoMet, and
3 μM [73As]-iAsIII, 0.26 μM E. coli thioredoxin (Trx) with 0.5 μM rat liver Trx reductase and
300 μM NADPH in 100 mM tris/100 mM Na phosphate buffer, pH 7.4, were incubated at 37°
C from 60 mins in the presence of 0–10 mM GSH. Percentages of arsenic present as (Black)
methylarsonic and (Gray) dimethylarsinic species are shown.
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Table 1
Multiple-Sequence Alignments of Human AS3MT and Eight Animal Homologues Illustrate Conserved Motifs
I, II, and III, Conserved Asp at I′, and Five Conserved Cys Residues. Underlined sequence is UbiE
methyltransferase domain. The sequences of seven species were from NCBI GenBank (accession numbers are
given in parentheses following species names): Homo sapiens (Q9HBK9); Pan troglodytes (XP_508007); Bos
taurus (NP_001030195); Rattus norvegicus (NP_543166); Mus musculus (AAH13468); Gallus gallus
(XP_421735); Strongylocentrotus purpuratus (XP_784275). The partial sequences of another two species were
from TIGR Gene Index Databases by querying human AS3MT cDNA with TBLASTX program: Rainbow trout
(TC70487); Ciona intestinalis (TC65300). The missed potential residues in the N-termini are indicated with
question marks (?)
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